Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 06/03/2026 GMT			5-day change	1st Jan Change
247.90 ^DKK	-0.30%		+4.20%	-23.78%

01:22am	Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports	RE
12:57am	Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports	RE

Press Releases

03-02	Novo Nordisk invests 432 million euros in expanding Wegovy production in Ireland	AQ
03-02	Election of employee representatives to the Board of Directors of Novo Nordisk A/S	GL
03-02	Novo Nordisk A/S - share repurchase programme	GL
03-02	Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland	GL
02-25	Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes	GL
02-24	Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China	GL
02-23	Novo Nordisk A/S - share repurchase programme	GL
02-23	Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved	GL
02-23	Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved	AQ
02-20	Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S	GL
02-19	NHS must keep medicine clawback down or lose investment, says Novo Nordisk boss	AQ
02-17	Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average	GL
02-17	Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer	AQ
02-16	Novo Nordisk A/S - share repurchase programme	GL
02-16	FDA Tightens The Belt On GLP-1 Compounding, Escalating Threat Of Enforcement	AQ
02-13	Oral Semaglutide And The GLP-1 Compounding Reckoning: From Regulatory Ambiguity To FDA Enforcement, DOJ Referrals, And Novo Nordisk's Case Against Hims & Hers	AQ
02-12	CEO of Novo Nordisk sees growth potential as Medicare starts reimbursing obesity drugs	AQ
02-11	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
02-11	Karolinska Institutet: Molecular patterns behind unstable atherosclerosis identified	AQ
02-10	Patents, Innovation & Where The Law Draws The Line	AQ
02-10	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
02-09	Novo Nordisk sues Hims & Hers over copies of Wegovy	AQ
02-09	Novo Nordisk A/S - share repurchase programme	GL
02-09	Novo Nordisk A/S - share repurchase programme	AQ
02-09	Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®	GL